Health activists are demanding that the Competition Commission reopen its investigation into pharmaceutical giant Vertex. They argue the company’s pricing and access strategies for its revolutionary cystic fibrosis drug, Trikafta, have created a deep and unjust divide. As a result, the treatment is out of reach for most South African patients. The commission dropped its initial probe into Vertex in…